• RadioGel™
      • RadioGel™
      • Clinical Trials
      • US FDA IDE Process Updates
      • Brachytherapy
    • IsoPet®
      • IsoPet®
      • Regional Clinics
      • IsoPet® Therapy
        • IsoPet® Therapy Dog • Cat Application
        • IsoPet® Therapy Equine Application
      • Animal Studies
        • Canine Studies
        • Feline Studies
        • Equine Studies
    • About
      • About
      • Contact
      • Management & Consultants
      • Advisory Boards
      • Board of Directors
      • Mission • Strategy
      • Industry Partners
      • Awards • Recognition
    • Investors
      • Investors
 (+1) 509.736.4000  
   Email Us
  • RadioGel™
    • RadioGel™
    • Clinical Trials
    • US FDA IDE Process Updates
    • Brachytherapy
  • IsoPet®
    • IsoPet®
    • Regional Clinics
    • IsoPet® Therapy
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • Animal Studies
      • Canine Studies
      • Feline Studies
      • Equine Studies
  • About
    • About
    • Contact
    • Management & Consultants
    • Advisory Boards
    • Board of Directors
    • Mission • Strategy
    • Industry Partners
    • Awards • Recognition
  • Investors
    • Investors

    Sitemap

    • RadioGel™
      • RadioGel™
      • Clinical Trials
      • US FDA IDE Process Updates
      • Brachytherapy
    • IsoPet®
      • IsoPet®
      • Regional Clinics
      • IsoPet® Therapy
        • IsoPet® Therapy Dog • Cat Application
        • IsoPet® Therapy Equine Application
      • Animal Studies
        • Canine Studies
        • Feline Studies
        • Equine Studies
    • About
      • About
      • Contact
      • Management & Consultants
      • Advisory Boards
      • Board of Directors
      • Mission • Strategy
      • Industry Partners
      • Awards • Recognition

    RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

    IsoPet® Therapy Application


    Brachytherapy Treatment


    Vivos Inc.
     - Investor Relations 

    Contact

    draggable-logo

    About | Privacy Policy | Cookie Policy | Sitemap
    © 2022 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
    Log out | Edit
    • Scroll to top